Vera Therapeutics (VERA) EBIT (2020 - 2026)

Vera Therapeutics has reported EBIT for 7 years, with the latest figure at -$125.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 118.79% year-over-year to -$125.1 million; the trailing twelve-month figure through Mar 2026 stood at -$383.4 million (down 560.68% YoY), and the FY2025 full-year result was -$315.5 million, down 887.37% from the prior year.
• EBIT for Q1 2026 stood at -$125.1 million, down from -$94.2 million in the prior quarter.
• The five-year high for EBIT was $86.3 million in Q4 2024, with the low at -$125.1 million in Q1 2026.
• Historically, EBIT has averaged -$30.1 million across 5 years, with a median of -$31.1 million in 2024.
• The largest YoY upside for EBIT was 332.86% in 2022 against a maximum downside of 260.92% in 2022.
• Vera Therapeutics' EBIT stood at $38.6 million in 2022, then soared by 41.96% to $54.8 million in 2023, then soared by 57.42% to $86.3 million in 2024, then sank by 209.15% to -$94.2 million in 2025, then tumbled by 32.83% to -$125.1 million in 2026.
• The last three EBIT figures came in at -$125.1 million (Q1 2026), -$94.2 million (Q4 2025), and -$83.9 million (Q3 2025), per Business Quant data.